

Lorlatinib CROWN

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



No QoL benefit

Serious and disabling adverse effects



Other adjustments



Long term plateau in the PFS curve

Lorlatinib CROWN

FINAL SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies

Therapeutic Indication: Treatment of adult patients with anaplastic lymphoma kinase (ALK) positive (NSCLC) previously not treated with an ALK inhibitor

Experimental Arm: Lorlatinib

Control Arm: Crizotinib

